|Bid||40.48 x 1800|
|Ask||40.52 x 1300|
|Day's Range||40.44 - 40.78|
|52 Week Range||31.43 - 48.25|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||40.88|
|Earnings Date||Feb 01, 2017 - Feb 06, 2017|
|Forward Dividend & Yield||1.89 (4.58%)|
|Ex-Dividend Date||May 14, 2020|
|1y Target Est||47.70|
Yahoo Finance's Anjalee Khemlani and Zack Guzman discuss COVID-19 vaccine maker Curevac's public debut and the UK Government signing vaccine deals with J&J and Novavax.
The United States is tying payments for COVID-19 vaccines to timing milestones for production and approval, according to public documents and a Trump administration official, putting pressure on drugmakers including Moderna Inc to meet ambitious targets. In a deal with Moderna announced this week, federal agencies negotiated a sliding scale of payments. The Cambridge, Massachusetts, biotech's $1.5-billion deal pays out in full if its vaccine receives regulatory clearance by January 31, 2021, according to filings.
U.S. cases show signs of slowing as experts project future containment.